Abstract
SARS-CoV-2 causes thrombotic microangiopathy (TMA) through the activation of an alternative and lectin complement pathway. TMA is one of the main reasons for acute kidney injury development in patients with COVID-19. In this study, we present 3 TMA cases with severe kidney injury triggered by SARS-CoV-2. In the absence of other TMA causes, we diagnosed the atypical hemolytic uremic syndrome, triggered by SARS-CoV-2 due to abnormal complement activation. Because of both coagulation factors activation, and the high level of D-dimer in patients with COVID-19, it is crucial to differentiate disseminated intravascular coagulation from TMA. The use of anticomplement therapies such as eculizumab should be considered in refractory cases of progressive COVID-19. Controlled clinical trials are required before a definitive statement can be made.
References
1.
Zhou
Y
, Lu
K
, Pfefferle
S
, Bertram
S
, Glowacka
I
, Drosten
C
, A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms
. J Virol
. 2010
;84
:8753
–64
. .2.
Walls
AC
, Park
YJ
, Tortorici
MA
, Wall
A
, McGuire
AT
, Veesler
D
. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
. Cell
. 2020
;181
:281
–92.e6
. .3.
Magro
C
, Mulvey
JJ
, Berlin
D
, Nuovo
G
, Salvatore
S
, Harp
J
, Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases
. Transl Res
. 2020
;220
:1
–13
.4.
Ville
S
, Le Bot
S
, Chapelet-Debout
A
, Blancho
G
, Fremeaux-Bacchi
V
, Deltombe
C
, Atypical HUS relapse triggered by COVID-19
. Kidney Int
. 2021
;99
:267
–9
.5.
Sharma
P
, Uppal
NN
, Wanchoo
R
, Shah
HH
, Yang
Y
, Parikh
R
, COVID-19-associated kidney injury: a case series of kidney biopsy findings
. J Am Soc Nephrol
. 2020
;31
:1948
–58
. .6.
Diao
B
, Wang
C
, Wang
R
, Feng
Z
, Zhang
J
, Yang
H
, Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
. Nat Commun
. 2021 May 4
;12
(1
):2506
.7.
Mahajan
R
, Lipton
M
, Broglie
L
, Jain
NG
, Uy
NS
. Eculizumab treatment for renal failure in a pediatric patient with COVID-19
. J Nephrol
. 2020 Sep 26
;33
:1373
–6
. .8.
Trimarchi
H
, Coppo
R
. COVID-19 and acute kidney injury in pediatric subjects: is there a place for eculizumab treatment?
J Nephrol
. 2020
;33
:1119
–20
. .9.
Loirat
C
, Frémeaux-Bacchi
V
. Atypical hemolytic uremic syndrome
. Orphanet J Rare Dis
. 2011
;6
:60
. .10.
Laurence
J
, Mulvey
JJ
, Seshadri
M
, Racanelli
A
, Harp
J
, Schenck
EJ
, Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
. Clin Immunol
. 2020
;219
:108555
. .11.
Wada
H
, Matsumoto
T
, Suzuki
K
, Imai
H
, Katayama
N
, Ibaal
T
, Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy
. Thromb J
. 2018
;16
:14
. .12.
Wada
H
. Disseminated intravascular coagulation
. Clin Chim Acta
. 2004
;344
(1–2
):13
–21
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
